Total Payments
$6,738
2024 Payments
$1,081
Companies
54
Transactions
411
Medicare Patients
5,586
Medicare Billing
$551,638
Payment Breakdown by Category
Food & Beverage$6,557 (97.3%)
Education$181.02 (2.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,557 | 403 | 97.3% |
| Education | $181.02 | 8 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $870.24 | 53 | $0 (2024) |
| GlaxoSmithKline, LLC. | $863.99 | 68 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $758.24 | 45 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $285.71 | 13 | $0 (2024) |
| Grifols USA, LLC | $278.52 | 14 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $268.79 | 23 | $0 (2020) |
| Gilead Sciences, Inc. | $255.43 | 14 | $0 (2024) |
| United Therapeutics Corporation | $229.30 | 11 | $0 (2024) |
| Genentech USA, Inc. | $219.70 | 16 | $0 (2019) |
| CSL Behring | $199.86 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,081 | 51 | AstraZeneca Pharmaceuticals LP ($141.42) |
| 2023 | $1,145 | 61 | AstraZeneca Pharmaceuticals LP ($169.36) |
| 2022 | $814.16 | 50 | AstraZeneca Pharmaceuticals LP ($109.08) |
| 2021 | $723.59 | 42 | Boehringer Ingelheim Pharmaceuticals, Inc. ($167.53) |
| 2020 | $290.28 | 19 | GlaxoSmithKline, LLC. ($58.37) |
| 2019 | $542.65 | 36 | GlaxoSmithKline, LLC. ($164.77) |
| 2018 | $1,086 | 78 | Sunovion Pharmaceuticals Inc. ($206.06) |
| 2017 | $1,055 | 74 | CSL Behring ($175.10) |
All Payment Transactions
411 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/16/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/03/2024 | Avadel CNS Pharmaceuticals, LLC | LUMRYZ (Drug) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | ||||||
| 11/27/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $29.00 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/18/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $14.64 | General |
| Category: HFCWO | ||||||
| 11/12/2024 | Philips North America LLC | (AK6) Vest Therapy (Device) | Food and Beverage | Cash or cash equivalent | $14.44 | General |
| Category: Medical Device | ||||||
| 11/11/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Pulmonology | ||||||
| 10/30/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: RESPIRATORY | ||||||
| 10/29/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/28/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: Respiratory | ||||||
| 10/24/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: Respiratory | ||||||
| 10/18/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: IMMUNOLOGY | ||||||
| 10/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: IMMUNOLOGY | ||||||
| 10/10/2024 | Vifor Pharma, Inc. | Zemaira (Drug) | Food and Beverage | In-kind items and services | $30.08 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 09/26/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $30.74 | General |
| Category: RESPIRATORY | ||||||
| 09/16/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $30.27 | General |
| Category: Immunology | ||||||
| 09/12/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: Diabetes | ||||||
| 09/10/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/10/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: RESPIRATORY | ||||||
| 09/05/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,654 | 1,834 | $325,426 | $129,848 |
| 2022 | 24 | 1,548 | 1,801 | $360,456 | $144,890 |
| 2021 | 22 | 1,153 | 1,439 | $328,197 | $142,994 |
| 2020 | 23 | 1,231 | 1,542 | $280,765 | $133,907 |
Total Patients
5,586
Total Services
6,616
Medicare Billing
$551,638
Procedure Codes
96
All Medicare Procedures & Services
96 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 142 | 172 | $34,400 | $20,547 | 59.7% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 45 | 45 | $54,000 | $20,103 | 37.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 201 | 218 | $32,700 | $19,126 | 58.5% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 30 | 30 | $39,000 | $13,574 | 34.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 47 | 82 | $70,118 | $12,661 | 18.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 72 | 72 | $20,448 | $10,822 | 52.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 182 | 185 | $10,315 | $4,903 | 47.5% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 302 | 309 | $14,805 | $4,715 | 31.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $7,232 | $3,743 | 51.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 35 | $5,915 | $3,166 | 53.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 49 | $4,900 | $2,886 | 58.9% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 63 | 67 | $4,690 | $2,369 | 50.5% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 101 | 110 | $4,950 | $1,813 | 36.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $3,934 | $1,714 | 43.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 28 | 28 | $2,800 | $1,483 | 53.0% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 59 | 61 | $3,355 | $1,474 | 43.9% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 22 | 22 | $2,200 | $1,106 | 50.3% |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | Office | 2023 | 37 | 40 | $3,200 | $1,021 | 31.9% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 48 | 56 | $1,400 | $756.00 | 54.0% |
| 94664 | Evaluation of use of breathing device | Office | 2023 | 51 | 57 | $1,425 | $700.56 | 49.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 39 | 44 | $1,364 | $414.18 | 30.4% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 34 | 39 | $1,170 | $319.30 | 27.3% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 46 | 46 | $690.00 | $284.74 | 41.3% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 22 | 22 | $415.00 | $147.84 | 35.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 65 | 181 | $109,055 | $30,353 | 27.8% |
About Dr. David Defeo, M.D
Dr. David Defeo, M.D is a Pulmonary Disease healthcare provider based in Winston Salem, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003851395.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Defeo, M.D has received a total of $6,738 in payments from pharmaceutical and medical device companies, with $1,081 received in 2024. These payments were reported across 411 transactions from 54 companies. The most common payment nature is "Food and Beverage" ($6,557).
As a Medicare-enrolled provider, Defeo has provided services to 5,586 Medicare beneficiaries, totaling 6,616 services with total Medicare billing of $551,638. Data is available for 4 years (2020–2023), covering 96 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Sleep Medicine, Critical Care Medicine
- Location Winston Salem, NC
- Active Since 06/19/2006
- Last Updated 03/25/2021
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1003851395
Products in Payments
- OFEV (Drug) $419.80
- ACTHAR (Biological) $374.51
- TRELEGY ELLIPTA (Drug) $363.95
- STIOLTO RESPIMAT (Drug) $294.67
- NUCALA (Biological) $287.36
- DUPIXENT (Biological) $258.81
- TYVASO (Drug) $229.30
- BEVESPI AEROSPHERE (Drug) $214.93
- Prolastin-C Liquid (Biological) $214.27
- BREZTRI (Drug) $179.88
- GLASSIA (Biological) $163.50
- Xolair (Biological) $121.66
- Arikayce (Drug) $110.10
- AIRSUPRA (Drug) $100.94
- BREO (Drug) $100.50
- Veklury (Drug) $99.79
- Esbriet (Biological) $98.04
- YUPELRI (Drug) $97.35
- Utibron (Drug) $96.19
- XOLAIR (Biological) $87.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Winston Salem
Jill Ohar, Md, MD
Pulmonary Disease — Payments: $365,275
Pulmonary Disease $365,275
Victor Ortega, M.d, M.D
Pulmonary Disease — Payments: $48,918
Pulmonary Disease $48,918
Kapilkumar Patel, M.d, M.D
Pulmonary Disease — Payments: $30,104
Pulmonary Disease $30,104
Dr. Christina Bellinger, Md, MD
Pulmonary Disease — Payments: $19,514
Pulmonary Disease $19,514
Dr. Benjamin Bregman, M.d, M.D
Pulmonary Disease — Payments: $13,437
Pulmonary Disease $13,437
Dr. Farhan Ahmed, M.d, M.D
Pulmonary Disease — Payments: $8,257
Pulmonary Disease $8,257